Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Rafferty Asset Management LLC

Rafferty Asset Management LLC cut its holdings in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 32.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 93,319 shares of the company's stock after selling 45,786 shares during the quarter. Rafferty Asset Management LLC owned about 0.16% of Twist Bioscience worth $4,337,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Van ECK Associates Corp increased its stake in Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after purchasing an additional 267 shares during the period. Banque Transatlantique SA acquired a new position in shares of Twist Bioscience during the fourth quarter worth about $43,000. US Bancorp DE increased its stake in shares of Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after acquiring an additional 601 shares during the period. KBC Group NV increased its stake in shares of Twist Bioscience by 71.4% during the fourth quarter. KBC Group NV now owns 2,942 shares of the company's stock worth $137,000 after acquiring an additional 1,226 shares during the period. Finally, Blue Trust Inc. increased its stake in shares of Twist Bioscience by 19.9% during the fourth quarter. Blue Trust Inc. now owns 4,567 shares of the company's stock worth $206,000 after acquiring an additional 757 shares during the period.

Twist Bioscience Price Performance

TWST stock traded up $0.10 during trading on Friday, reaching $28.26. 781,842 shares of the company were exchanged, compared to its average volume of 977,464. The company has a market cap of $1.69 billion, a P/E ratio of -8.36 and a beta of 2.54. Twist Bioscience Co. has a 52-week low of $27.12 and a 52-week high of $60.90. The stock's 50 day moving average price is $36.71 and its 200 day moving average price is $42.83. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The company had revenue of $92.79 million for the quarter, compared to analysts' expectations of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. As a group, analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TWST has been the topic of a number of recent analyst reports. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. JPMorgan Chase & Co. dropped their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. The Goldman Sachs Group dropped their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Barclays dropped their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Finally, Guggenheim reiterated a "buy" rating and set a $50.00 price target on shares of Twist Bioscience in a research note on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $50.40.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, insider Dennis Cho sold 689 shares of the company's stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $25,940.85. Following the sale, the insider now owns 110,849 shares of the company's stock, valued at $4,173,464.85. This represents a 0.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Adam Laponis sold 936 shares of the company's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total transaction of $27,846.00. Following the completion of the sale, the chief financial officer now directly owns 106,018 shares in the company, valued at $3,154,035.50. This trade represents a 0.88% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,011 shares of company stock valued at $951,499 over the last quarter. Corporate insiders own 3.01% of the company's stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.